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The intern on the phone said: “We’ve got this kid down in 
Emergency with no blood pressure, and he’s sitting here talking to us 
like nothing is wrong.” It was 1973, and I was a cardiology fellow at 
Emory University in Atlanta, covering the acute cardiac units that 
evening at Grady Memorial Hospital.
He was 22 years old and had osteogenesis imperfecta: the blue 
sclera, the brittle bones, and other features of the syndrome, including 
a triangular face, hyperextensible joints, and a mild clotting 
abnormality. He came from a small town in rural Georgia, where he 
had defied his condition by playing quarterback on his high school 
football team. He was too small for football anyway at 66 inches and 
125 pounds, even without considering the risk of broken bones. 
Between the ages of 15 and 16 he had sustained 6 fractures.
Osteogenesis imperfecta covers a wide spectrum of clinical 
severity ranging from death in utero to only mild bone abnormalities 
and a normal lifespan. A 1979 classification defined 4 types, from mild 
to lethal, based upon clinical and radiographic features. At least 17 
different genetic defects have now been identified, including 8 that are
autosomal recessive, although the most common one is autosomal 
dominant with variable penetrance.1 A functional classification groups 
the genetic abnormalities into 5 categories: (1) defects in collagen 
synthesis, structure, or processing, (2) defects in collagen modification,
(3) defects in collagen folding and cross-linking, (4) defects in bone 
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mineralization, and (5) defects in osteoblast development with 
collagen insufficiency.1 
Nowadays bisphosphonates are widely used to treat 
osteogenesis imperfecta, with the goal of increasing bone volume, 
even if bone quality is still impaired. Whether this therapy reduces long
bone fractures is uncertain because the number of subjects included in
placebo-controlled trials is small (n=424).1 Aortic and mitral 
regurgitation are the most common cardiac abnormalities seen in this 
condition. In one echocardiographic study 10% of adults with 
osteogenesis imperfecta had severe and 10% had moderate aortic 
regurgitation, while 7% had moderate mitral regurgitation.2 
I don’t remember all of the details of my patient’s history, but 
can refer back to the published case report.3 A heart murmur was 
heard when he was 15, and 3 years later he gradually developed 
exertional dyspnea and fatigue, followed within a year by orthopnea. 
Physical examination at that time suggested severe aortic and mitral 
regurgitation, and this was confirmed by cardiac catheterization. He 
underwent aortic and mitral valve replacement, complicated by 
prolonged oozing that required reopening his chest.
One year later he developed progressive cardiomegaly, without 
symptomatic deterioration. A repeat catheterization showed that his 
valves were functioning normally, but levophase filming after a 
pulmonary artery injection showed left ventricular dilatation and 
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dysfunction so severe that the ejection fraction could not be 
calculated. He returned to his previous level of activity and denied all 
symptoms except dyspnea on exertion.
It was 9 months later, 21 months after surgery, when he walked 
into the Emergency Department complaining increased dyspnea, 
fatigue and edema. I was confident that with meticulous, tailored 
therapy I could improve his heart failure. I worked to optimize his 
oxygenation, his hemoglobin level, his heart rate, his preload and 
afterload, and to reduce the work of breathing. I used inotropes 
carefully, beginning with small doses. I stayed at his bedside, making 
adjustments minute to minute.
He talked about his family, his girlfriend, his hopes and plans for 
the future. He did not mention osteogenesis imperfecta or anything 
else about his medical circumstances. In response to questions as to 
whether he was warm enough, was his breathing better, did he have 
pain anywhere, the response was always the same: “I’m OK.” Our 
corner of the ICU seemed unusually quiet with just me, my patient, and
a very competent nurse. As the night wore on, it became increasingly 
obvious that he was not getting better. After midnight he became 
quieter, and then somnolent. He passed away 8 hours after admission. 
Nothing that I had done had influenced his clinical course in any 
meaningful way.
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Treatment of acute heart failure in 1973 was based upon faulty 
assumptions, and sometimes caused more harm than good. One area 
of research was focused on finding a measure of contractility in 
animals or patients that was independent of loading conditions.4 
Maximum dp/dt during isovolumic contraction, and vmax, defined as the 
theoretical maximum velocity of contraction, were oft discussed 
possibilities. The idea was that such a measurement would allow a 
better assessment of inotropic drugs, and the future was bright 
because such drugs were under development.
Beta-blockers had become available in the late 1960’s and were 
enthusiastically embraced for the treatment of angina and some 
arrhythmias. Beta-blockers were avoided in patients with heart failure, 
and if a patient with even a hint heart failure needed a beta-blocker for
angina, digitalis was sometimes given concomitantly. It was thought 
that elevated catecholamine levels preserved cardiac output in 
compensated heart failure, and that blocking them invited disaster. 
The notion that beta-blockers would be safe and effective treatment 
for heart failure would have been met with incredulity by any 
cardiologist in that era.
So, our approach to heart failure was 180 degrees wrong. Not 
that it would have made a difference to my patient at the time I saw 
him. Our approach to sudden cardiac death was to focus on the 
eradication of ventricular arrhythmias with anti-arrhythmic drugs for 
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high-risk patients, and that turned out to be very wrong as well.5 
Misdirected therapies occurred in other branches of medicine also; for 
example, peptic ulcer disease was treated for decades with vagotomy 
and pyloroplasty when the cause was H. Pylori infection.
Are we making any huge mistakes like this in modern cardiology?
We have accumulated so much knowledge. We have an array of 
precise imaging techniques. We have a multitude of carefully 
conducted clinical trials that form the basis for well-considered 
guidelines. Surely we know what we are doing now.
Sometimes I think back with wonder and admiration to a teenage
boy with osteogenesis imperfecta playing quarterback for his high-
school football team, long ago, in rural Georgia. He must have felt like 
such an outsider because of his genetic condition, but as quarterback, 
he could belong.
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